Answers are grounded in this paper and cite their sources.
A computational framework develops selective pi3kα inhibitors as novel anticancer agents, suggesting improved safety and efficacy.
Phosphatidylinositol 3-kinase (PI3K) has emerged as a promising target for the development of new anticancer drugs. Selective inhibition of the PI3Kα isoform is considered a favourable strategy, providing not only the required efficacy but also a potentially improved safety profile. Modern CADD (Computer Aided Drug Design) methodologies, incorporating both ligand-based and structure-based approaches, offer valuable guidance for the design of novel PI3Kα inhibitors. Benzoxazepine and thiazole derivatives were investigated through a combination of molecular dynamics, ensemble docking, and 3D-QSAR (Three-Dimensional Quantitative Structure–Activity Relationship) studies to identify structural features critical for PI3Kα activity and selectivity over PI3Kβ, PI3Kγ, and PI3Kδ. Subsequently, scaffold-hopping and R-group replacement were applied to design structurally diverse, potentially selective PI3Kα inhibitors with these defined characteristics. A structure-based virtual screening protocol was also implemented to identify new moieties with selective PI3Kα inhibitory potential. The study defined new chemotypes capable of binding to αVal851 in the hinge region, crucial for PI3Kα inhibition, including chromeno[3,4-d]imidazole, 2H-benzo[b][1,4]oxazine, and quinoline derivatives. Additional substructures binding to the hydrophobic region, particularly αGln859, contributed to isoform selectivity as shown by 3D-QSAR predictions. Compounds identified by virtual screening also displayed interactions with the hinge region and non-conserved amino acids, further supporting selective PI3Kα inhibition. Overall, this study establishes a comprehensive CADD framework and presents a series of rationally designed PI3Kα inhibitors with improved predicted selectivity profiles, providing a foundation for the future development of targeted therapies.
No takes yet. Share an insight, caveat, or question.
Jovanović et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: